MCM
FATE icon

Moore Capital Management’s Fate Therapeutics FATE Stock Holding History

Moore Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-29,993
Closed -$672K – 580
2022
Q3 		$672K Buy
+29,993
New +$867K 0.02% 426
2022
Q2 		– Sell
-22,943
Closed -$890K – 724
2022
Q1 		$890K Buy
+22,943
New +$888K 0.02% 437
2021
Q3 		– Sell
-25,000
Closed -$2.17M – 823
2021
Q2 		$2.17M Sell
25,000
-23,431
-48% -$1.89M 0.03% 450
2021
Q1 		$3.99M Sell
48,431
-31,129
-39% -$2.98M 0.05% 318
2020
Q4 		$7.23M Buy
79,560
+29,560
+59% +$1.84M 0.08% 175
2020
Q3 		$2M Hold
50,000
– – 0.04% 265
2020
Q2 		$1.72M Buy
50,000
+25,900
+107% +$772K 0.05% 197
2020
Q1 		$535K Buy
+24,100
New +$609K 0.02% 139

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Moore Capital Management's FATE Position: Q4 2022 in Review

Moore Capital Management sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 29,993 shares — an estimated $672K sold.

Moore Capital Management first reported a position in FATE in Q1 2020 and held it in 8 quarters. The position peaked at $7.23M in Q4 2020. 227 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

  • Moore Capital Management reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Moore Capital Management sold 29,993 Fate Therapeutics shares in Q4 2022, an estimated $672K.
  • Moore Capital Management first reported a position in Fate Therapeutics in Q1 2020 and held it in 8 quarters.
  • Moore Capital Management's Fate Therapeutics position peaked at $7.23M in Q4 2020.
  • 227 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on Moore Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.